Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 5Genitourinary 3Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 3Prostatic Hyperplasia 1Osteoporosis 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Risedronic Acid × Genitourinary × Clear all
NCT00859027 2018-05-01

Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

UConn Health

Phase 4 Completed
50 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT00043069 2016-12-07

Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
71 enrolled
Genitourinary

Osteoporosis, Prostatic Neoplasms

NCT00426777 2012-02-03

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

CMX Research

Phase 3 Completed
160 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡